拉西地平对高血压并发冠心病患者血浆同型半胱氨酸水平的影响

Effect of Lacidipine on Serum Homocysteine Level of Patients with Hypertention Complicated with Coronary Heart Disease

目的研究拉西地平对高血压并发冠心病患者血浆同型半胱氨酸(Hcy)水平的影响。方法高血压并发冠心病患者184例,随机分为治疗组93例与对照组91例。治疗组给予拉西地平4 mg,qd,po;对照组给予硝苯地平缓释片,每次10 mg,bid,po。疗程均为3个月。治疗前后监测血压及血浆Hcy水平。结果治疗组治疗前血浆Hcy水平(17.3±5.1)μmol.L-1,对照组为(16.9±4.8)μmol.L-1,治疗3个月后,治疗组平均血浆Hcy水平为(12.5±4.2)μmol.L-1,对照组为(14.6±4.4)μmol.L-1,两组Hcy水平均有显著降低,差异有统计学意义(P<0.01),两组间治疗后比较,差异有统计学意义(P<0.01)。结论拉西地平可降低高血压并发冠心病患者血浆Hcy水平,此作用独立于其降压作用之外,可能为拉西地平抗动脉粥样硬化的独特作用机制之一。

Objective To investigate the effect of lacidipine on serum homocysteine level of patients with hypertention and coronary heart disease. Methods One hundred eighty-four eligible patients were randomly divided into treatment group （93 patients） and control group（91 patients）. The patients in the treatment group were given with lacidipine 4 mg once a day and those in the control were treated with nifedpineines 10 mg twice a day. The duration of therapy was 3- month. The blood pressure and serum homocysteine level pre- and post-treatment were measured. Results The serum Hcy level of treatment group was （ 17.3±5. 1 ） μmol · L^-1 before treatment, and the control group was （16.9±4.8） μmol · L^-1;the three months later, which in the treatment group was （12.5±4.2） μmol · L^-1, in the control group was （14.6±4.4） μmol · L^-1, and the difference was remarkable（P〈0.01）. Lacidipine was better in decreasing the Hcy level than nifedpineines （P〈0. 01 ）. Conclusion Comparing with other calcium antagonists, the effect of lacidipine on reduction serum homocysteine level in hypertensive patient with coronary heart disease is much better and is independent of hypertension-lowering, which may be one of the unique mechanisms of its anti-arteriosclerosis.